Press Releases

Date Title
Toggle Summary Aeglea BioTherapeutics to Present a Poster at the Society for Immunotherapy of Cancer 2016 Annual Meeting Suggesting Potential for AEB1102 Combination Therapy with Immuno-Oncology Checkpoint Inhibitors
AUSTIN, Texas , Nov. 08, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat genetic rare diseases and cancer, today announced findings from a preclinical study
Toggle Summary Aeglea BioTherapeutics to Present New Data on AEB3103 at American Society of Hematology (ASH) 58th Annual Meeting
AUSTIN, Texas , Nov. 03, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat genetic rare diseases and cancer, today announced that it will present preclinical
Toggle Summary Aeglea BioTherapeutics Doses First Patients in Phase 1 Trial of AEB1102 for the Treatment of Arginase I Deficiency
– Top-Line Data is Anticipated in the First Half of 2017 – AUSTIN, Texas , Sept. 15, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat genetic rare diseases
Toggle Summary Aeglea BioTherapeutics Appoints Leading Experts to Inaugural Scientific Advisory Board
AUSTIN, Texas , Sept. 07, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare disease and cancer, today announced the appointment of leading experts to its
Toggle Summary Aeglea BioTherapeutics to Present at the 2016 Wells Fargo Healthcare Conference
AUSTIN, Texas , Sept. 01, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare disease and cancer, today announced that its chief executive officer, David G.
Toggle Summary Aeglea BioTherapeutics Doses First Patient in Phase 1 Trial of AEB1102 for the Treatment of Hematological Malignancies
Company Expands Profile of AEB1102 into Second Cancer Type AUSTIN, Texas , Aug. 29, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare diseases and cancer,
Toggle Summary Aeglea BioTherapeutics Announces Second Quarter 2016 Financial Results
AUSTIN, Texas , Aug. 09, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. , (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare diseases and cancer, today reported financial results for the quarter ended
Toggle Summary Aeglea BioTherapeutics Provides Update on AEB1102 Clinical Program in Rare Diseases and Cancer
--EMA Issued a Positive Opinion for Orphan Drug Designation for AEB1102-- --Initiated Two Phase 1 Clinical Trials of AEB1102 for Treatment of Hyperargininaemia and Hematological Malignancies-- AUSTIN, Texas , July 18, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc.
Toggle Summary Aeglea BioTherapeutics Receives FDA Fast Track Designation for AEB1102 for the Treatment of Patients with Hyperargininemia Secondary to Arginase I Deficiency
AUSTIN, Texas , May 23, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. , (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, today announced it received Fast Track
Toggle Summary Aeglea BioTherapeutics To Present at the UBS 2016 Global Healthcare Conference
AUSTIN, Texas , May 20, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. , (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, today announced that management will be
Toggle Summary Aeglea BioTherapeutics Announces First Quarter 2016 Financial Results
AUSTIN, Texas , May 19, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. , (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, today reported financial results for the
Toggle Summary Aeglea BioTherapeutics Names Dr. Sandra Rojas-Caro as Chief Medical Officer
AUSTIN, Texas , May 16, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. , (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, today announced it has named Sandra
Toggle Summary Aeglea BioTherapeutics to Present New Data at American Association for Cancer Research (AACR) Annual Meeting
AUSTIN, Texas , April 19, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, today announced that it will present in a
Toggle Summary Aeglea BioTherapeutics to Present New Data at American Association for Cancer Research (AACR) Annual Meeting
AUSTIN, Texas, April 18, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, today announced that it will present in a
Toggle Summary Aeglea BioTherapeutics Announces Closing of Initial Public Offering and Partial Exercise of the Underwriters’ Option
AUSTIN, Texas , April 12, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, today announced the closing of its initial